Summary
GlobalData, the industry analysis specialist, has released a new report "Addiction Control-Drug Pipeline Analysis and Market Forecasts to 2015". The report is an essential source of information and analysis on the global addiction control market. The report identifies the key trends shaping and driving the global addiction control market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global addiction control sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.
Scope
The scope of the report includes:
-Annualized global addiction control market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
-Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include nicotinic acetylcholine receptors receptor targetters, dopamine-serotonin receptor targetters, GABA receptors targetters, adrenergic receptors targetters, opioid receptor targetters and cannabinoid receptor targetters.
-Analysis of the current and future market competition in the global addiction control market. Key market players covered are Eli Lilly and Company, GSK, Alkermes pharmaceuticals, Nicobrand (Watson Pharmaceuticals) and Titan pharmaceuticals.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with addiction control.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global addiction control market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global addiction control market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
What's the next big thing in the global addiction control market landscape? -Identify, understand and capitalize.
Table of Contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Addiction Control Market: Market Characterization
2.1 Overview
2.2 Addiction Control Market Size
2.3 Addiction Control Market Forecast and CAGR
2.4 Drivers and Barriers for Addiction Control Market
2.4.1 Drivers for Addiction Control Market
2.4.2 Barriers for Addiction Control Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway
3 Addiction Control Market: Competitive Assessment
3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed Products in Alcohol Dependence Market
3.3.1 Vivitrol (naltrexone)
3.3.2 Campral (acamprosate calcium)
3.3.3 Antabuse (disulfiram)
3.4 Product Profile for the Major Marketed Products in Nicotine Addiction Market
3.4.1 Chantix/Champix (varenicline)
3.4.2 Zyban (bupropion)
3.4.3 NRTs (Nicotine replacement therapies)
3.5 Product Profile for the Major Marketed Products in Drug Abuse Market
3.5.1 Suboxone/Subutex (naloxone+buprenorphine/buprenorphine)
3.5.2 Methadone
3.6 Key Takeaway
4 Addiction Control Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline Assessment
4.2.1 Technology Trends Analytic Framework
4.3 Addiction Control Therapeutics –Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development for Alcohol Dependence
4.4.1 Topiramate
4.4.2 Revex/Nalmefene
4.5 Molecule Profile for Promising Drugs under Clinical Development for Nicotine Addiction
4.5.1 NIC-VAX
4.5.2 TA-NIC
4.5.3 TA-CD
4.5.4 Divalproex
4.6 Addiction Control Therapeutics Market-Clinical Pipeline by Mechanism of Action
4.7 Addiction Control Pipeline-Pipeline by Clinical Phases of Development
4.7.1 Addiction Control Therapeutics-Regulatory and Phase III Clinical Pipeline
4.7.2 Addiction Control Therapeutics-Phase II Clinical Pipeline
4.7.3 Addiction Control Therapeutics-Phase I Clinical Pipeline
4.7.4 Addiction Control Therapeutics-Preclinical and Discovery Pipeline
4.8 Discontinued/Suspended Drugs for Addiction Control
4.9 Key Takeaway
5 Addiction Cotrol Market: Implications for Future Market Competition
6 Addiction Control Market: Future Players in Addiction Control Market
6.1 Introduction
6.2 GlaxoSmithKline
6.2.1 Overview
6.2.2 CNS Portfolio
6.2.3 Addiction Control Portfolio
6.3 Eli Lilly
6.3.1 Overview
6.3.2 CNS Portfolio
6.3.3 Addiction Control Portfolio
6.4 Alkermes
6.4.1 Overview
6.4.2 CNS Portfolio
6.4.3 Addiction Control Portfolio
6.5 Titan Pharmaceuticals
6.5.1 Overview
6.5.2 CNS Portfolio
6.5.3 Addiction Control Portfolio
6.6 Nicobrand (Watson Pharmaceuticals)
6.6.1 Overview
6.6.2 CNS Portfolio
6.6.3 Addiction Control Portfolio
7 Addiction Control Market: Appendix
7.1 Market Definitions
7.2 Abbreviations
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Primary Research
7.3.5 Expert Panels Validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources
List of Tables
1.1 List of Tables
Table 1: Global Addiction Control Therapeutics Market, Revenue ($m), 2000-2015
Table 2: Major Marketed Products Comparison in Addiction Control Market, 2009
Table 3: Addiction Control Therapeutics-Most Promising Drugs Under Clinical Development, 2009
Table 4: Addiction Control Therapeutics-Regulatory and Phase III Clinical Pipeline-Alcohol Dependence, 2009
Table 5: Addiction Control Therapeutics-Regulatory and Phase III Clinical Pipeline-Nicotine Addiction, 2009
Table 6: Addiction Control Therapeutics-Regulatory and Phase III Clinical Pipeline-Drug Abuse, 2009
Table 7: Addiction Control Therapeutics-Phase II Clinical Pipeline-Alcohol Dependence, 2009
Table 8: Addiction Control Therapeutics-Phase II Clinical Pipeline-Nicotine Addiction, 2009
Table 9: Addiction Control Therapeutics-Phase II Clinical Pipeline-Drug Abuse, 2009
Table 10: Addiction Control Therapeutics-Phase I Clinical Pipeline-Alcohol Dependence
Table 11: Addiction Control Therapeutics-Phase I Clinical Pipeline-Nicotine Addiction, 2009
Table 12: Addiction Control Therapeutics-Phase I Clinical Pipeline-Drug Abuse, 2009
Table 13: Addiction Control Therapeutics-Preclinical and Discovery Pipeline-Alcohol Dependence, 2009
Table 14: Addiction Control Therapeutics-Preclinical and Discovery Pipeline-Nicotine Addiction, 2009
Table 15: Addiction Control Therapeutics-Preclinical and Discovery Pipeline-Drug Abuse, 2009
Table 16: List of Discontinued Drugs for Addiction Control, 2009
Table 17: GlaxoSmithKline-CNS Marketed Products, 2009
Table 18: GlaxoSmithKline-CNS Pipeline Products, 2009
Table 19: Eli Lilly-CNS Marketed Products, 2009
Table 20: Eli Lilly-CNS Pipeline Products, 2009
Table 21: Alkermes-CNS Marketed Products, 2009
Table 22: Alkermes-CNS Pipeline Products, 2009
Table 23: Titan Pharmaceuticals-CNS Marketed Products, 2009
Table 24: Titan Pharmaceuticals-CNS Pipeline Products, 2009
Table 25: Nicobrand-CNS Marketed Products, 2009
Table 26: Nicobrand-CNS Pipeline Products, 2009
List of Figures
1.2 List of Figures
Figure 1: Global Addiction Control Therapeutics Market, Revenue ($m), 2000-2015
Figure 2: Opportunity and Unmet Need in the Alcohol Dependence Market, 2009
Figure 3: Opportunity and Unmet Need in the Nicotine Addiction Market, 2009
Figure 4: Opportunity and Unmet Need in the Drug Abuse Market, 2009
Figure 5: Opportunity and Unmet Need in the Addiction Control Market, 2009
Figure 6: Strategic Competitor Assessment of the Major Marketed Products in Addiction Control, 2009
Figure 7: Technology Trends Analytic Framework of the Alcohol Dependence Pipeline, 2009
Figure 8: Technology Trends Analytic Framework of the Nicotine Addiction Pipeline, 2009
Figure 9: Technology Trends Analytic Framework of the Drug Abuse Pipeline, 2009
Figure 10: Technology Trends Analytic Framework of the Alcohol Dependence Pipeline-Description, November 2009
Figure 11: Technology Trends Analytic Framework of the Nicotine Addiction Pipeline-Description, 2009
Figure 12: Technology Trends Analytic Framework of the Drug Abuse Pipeline-Description, 2009
Figure 13: Addiction Control Therapeutics Market-Clinical Pipeline by Mechanism of Action, 2009
Figure 14: Addiction Control Pipeline by Phase of Clinical Development, 2009
Figure 15: Implications for Future Market Competition in the Addiction Control, 2009
Figure 16: GlobalData Methodology
Figure 17: GlobalData Market Forecasting Model
